TrialAnnals of the rheumatic diseases2014

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Arthur Kavanaugh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.